

IF

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant: Lachance et al.

Serial No. 10/558,909

Filed: December 1, 2005

For: Cycloalkanepyrrolopyridines as DP Receptor Antagonists

Art Unit: 1614

Examiner: TBA

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By Jeri Schiffman Date 7/2/07

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:


RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application *and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.*
- ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,



By: Dianne Brown

Attorney _____ For Applicant(s)

Reg. No. 42,068

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594- 1249

Date: July 2, 2007

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

JUL 05 2007
(use as)

(use as ~~many~~ sheets as necessary)

Sheet

1

of

3

Attorney Docket Number

MC083P

COMPLETE IF KNOWN**Application Number**

10/558,909

Filing Date

December 1, 2005

First Named Inventor

Nicolas Lachance

Group Art Unit

1614

Examiner Name

To be assigned

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]Examiner
SignatureDate
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/28/2007

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	10/558,909	
			Filing Date	December 1, 2005	
			First Named Inventor	Nicolas Lachance	
			Group Art Unit	1614	
			Examiner Name	To be assigned	
Sheet	2	of	3	Attorney Docket Number	MC083P

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	F	Coleman et al., "Prostanoid Receptors, Classification, Characterisation and Therapeutic Relevance", Eicosanoids: From Biotechnology to Therapeutic Applications, Ch. 14, pages 137-154, Folco et al. eds., Plenum Press, New York, 1996
	G	Ichikawa et al., "Molecular aspects of the structures and functions of the prostaglandin E receptors", Journal of Lipid Mediators and Cell Signalling, 14:83-87, 1996
	H	Tsuri et al., "Bicyclo[2.2.1]heptane and 6,6-Dimethylbicyclo[3.1.1]heptane Derivatives: Orally Active, Potent, and Selective Prostaglandin D2 Receptor Antagonists", Journal of Medicinal Chemistry, 40:3504-3507, 1997
	I	Matsuoka et al., "Prostaglandin D2 as a Mediator of Allergic Asthma", Science, 287:2013-2017, 2000
	J	Kelly et al., "Azaindoles", Canadian Journal of Chemistry, 44:2455-2459, 1966
	K	Estel et al., "Metalation/SRN1 Coupling in Heterocyclic Synthesis. A Convenient Methodology for Ring Functionalization", J. Org. Chem., 53:2740-2744, 1988
	L	Chen et al., "Syntheses of Indoles via a Palladium-Catalyzed Annulation between Iodoanilines and Ketones", J. Org. Chem., 62:2676-2677, 1997
	M	Short et al., "General Method of Synthesis of Cyclopentanoid Terpenic Acids. . .", J. Org. Chem., 48:4453-4461, 1983
	N	Jefford et al., "The Alkylation of Silyl Enol Ethers with SN1-Unreactive Iodides in the Presence of Silver Trifluoroacetate", Tetrahedron Letters, 33(14):1855-1858, 1992
	O	Begley et al., "Application of the Intramolecular Wadsworth-Emmons Reaction . . .", Tetrahedron, 37(25):4503-4508, 1981
	P	Unangst et al., "Synthesis of Novel 5-Hydroxy-3-alkoxy-and 5-Hydroxy-3-alkylthioindole-2-carboxamides", J. Heterocyclic Chem., 33:1627-1630, 1996
	Q	Stille, J., "The Palladium-Catalyzed Cross-Coupling Reactions of Organotin Reagents with Organic Electrophiles", Angew. Chem., Int. Ed. Engl., 25:508-524, 1986
	R	Farina et al., "Large Rate Accelerations in the Stille Reaction with Tri-2-furylphosphine and Triphenylarsine as Palladium Ligands: Mechanistic and Synthetic Implications", J. Am. Chem. Soc., 113:9585-9595, 1991
	S	McFarlane et al., "Effects of a Contractile Prostaglandin Antagonist (L-640,035) Upon Allergen-Induced Bronchoconstriction in Hyperreactive Rats and Conscious Squirrel Monkeys", Prostaglandins, 28 (2):173-182, 1984
	T	McFarlane et al., "Effects of a 5-lipoxygenase inhibitor (L-651,392) on primary and late pulmonary responses to ascaris antigen in the squirrel monkey", Agents and Actions, 22:63-68, 1987

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/28/2007

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	10/558,909
				Filing Date	December 1, 2005
				First Named Inventor	Nicolas Lachance
				Group Art Unit	1614
				Examiner Name	To be assigned
Sheet	3	of	3	Attorney Docket Number	MC083P

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/28/2007